title: Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
authors.affiliation: Fovea Pharmaceuticals, Inc. NewYork, NY 10174, USA.
authors.forename: Barrett
authors.initials: B
authors.lastname: Katz
authors.forename: Mauro
authors.initials: M
authors.lastname: Goldbaum
mesh_terms: D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D015861:Retinal Neovascularization / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib